Bortezomib alleviates drug-induced liver injury by regulating CYP2E1 gene transcription

Park,Woo-Jae; Kim,So-Yeon; Kim,Ye-Ryung; Park,Joo-Won

doi:10.3892/ijmm.2016.2461

Bortezomib alleviates drug-induced liver injury by regulating CYP2E1 gene transcription

Authors:
- Woo-Jae Park
- So-Yeon Kim
- Ye-Ryung Kim
- Joo-Won Park
View Affiliations

Affiliations: Department of Biochemistry, School of Medicine, Gachon University, Incheon 406-799, Republic of Korea, Department of Biochemistry, School of Medicine, Ewha Womans University, Yang Cheon-Gu, Seoul 158-710, Republic of Korea
Published online on: January 20, 2016 https://doi.org/10.3892/ijmm.2016.2461
Pages: 613-622
Copyright: © Park et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute liver failure, i.e., the fatal deterioration of liver function, is the most common indication that emergency liver transplantation is necessary. Moreover, in the USA, drug-induced liver injury (DILI), including acetaminophen (APAP)-induced hepatotoxicity, is the main cause of acute liver failure. Matching a donor for liver transplantation is extremely difficult, and thus the development of a novel therapy for DILI is urgently needed. Following recent approval by the FDA of the proteasomal inhibitor bortezomib, its therapeutic effects on various human diseases, including solid and hematologic malignancies, have been validated. However, the specific action of proteasomal inhibition in cases of DILI had not been elucidated prior to this study. To examine the effects of proteasomal inhibition in DILI experimentally, male C56Bl/6 mice were injected with 1 mg bortezomib/kg before APAP treatment. Bortezomib not only alleviated APAP-induced hepatotoxicity in a time- and dose-dependent manner, it also alleviated CCl4- and thioacetamide-induced hepatotoxicity. We also noted that bortezomib significantly reduced cytochrome P450 2E1 (CYP2E1) expression and activity in the liver, which was accompanied by the induction of endoplasmic reticulum (ER) stress. In addition, bortezomib decreased hepatocyte nuclear factor‑1α-induced promoter activation of CYP2E1 in Hep3B cells. By contrast, another proteasome inhibitor, MG132, did not cause ER stress and did not markedly affect CYP2E1 enzyme activity. Liver injury induced by APAP was aggravated by MG132, possibly via elevation of connexin 32 expression. This study suggests that proteasome inhibition has different effects in cases of DILI depending on the specific inhibitor being used. Furthermore, results from the mouse model indicated that bortezomib, but not MG132, was effective in alleviating DILI. ER stress induced by proteasome inhibition has previously been shown to exert various effects on DILI patients, and thus each available proteasomal inhibitor should be evaluated individually in order to determine its potential for clinical application.

View Figures

View References

1	Bernal W, Auzinger G, Dhawan A and Wendon J: Acute liver failure. Lancet. 376:190–201. 2010. View Article : Google Scholar : PubMed/NCBI
2	Hinson JA, Roberts DW and James LP: Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol. 369–405. 2010. View Article : Google Scholar :
3	James LP, Alonso EM, Hynan LS, Hinson JA, Davern TJ, Lee WM, Squires RH, Pediatric Acute, Liver Failure and Study Group: Detection of acetaminophen protein adducts in children with acute liver failure of indeterminate cause. Pediatrics. 118:e676–e681. 2006. View Article : Google Scholar : PubMed/NCBI
4	Burcham PC and Harman AW: Acetaminophen toxicity results in site-specific mitochondrial damage in isolated mouse hepatocytes. J Biol Chem. 266:5049–5054. 1991.PubMed/NCBI
5	Adams J: The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 29(Suppl 1): 3–9. 2003. View Article : Google Scholar : PubMed/NCBI
6	Richardson PG, Mitsiades C, Hideshima T and Anderson KC: Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 57:33–47. 2006. View Article : Google Scholar : PubMed/NCBI
7	Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, et al: A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs. 32:323–329. 2014. View Article : Google Scholar :
8	Blouin JM, Duchartre Y, Costet P, Lalanne M, Ged C, Lain A, Millet O, de Verneuil H and Richard E: Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria. Proc Natl Acad Sci USA. 110:18238–18243. 2013. View Article : Google Scholar : PubMed/NCBI
9	Li Z, Wu Q, Yan Z, Li D, Lu G, Mou W, Wu S, Pan X, Lu Q and Xu K: The protection and therapy effects of bortezomib in murine acute graft-versus-host disease. Transplant Proc. 45:2527–2535. 2013. View Article : Google Scholar : PubMed/NCBI
10	Park WJ, Park JW, Erez-Roman R, Kogot-Levin A, Bame JR, Tirosh B, Saada A, Merrill AH Jr, Pewzner-Jung Y and Futerman AH: Protection of a ceramide synthase 2 null mouse from drug-induced liver injury: role of gap junction dysfunction and connexin 32 mislocalization. J Biol Chem. 288:30904–30916. 2013. View Article : Google Scholar : PubMed/NCBI
11	Wagner-Ballon O, Pisani DF, Gastinne T, Tulliez M, Chaligné R, Lacout C, Auradé F, Villeval JL, Gonin P, Vainchenker W and Giraudier S: Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood. 110:345–353. 2007. View Article : Google Scholar : PubMed/NCBI
12	Carvalho AN, Marques C, Rodrigues E, Henderson CJ, Wolf CR, Pereira P and Gama MJ: Ubiquitin-proteasome system impairment and MPTP-induced oxidative stress in the brain of C57BL/6 wild-type and GSTP knockout mice. Mol Neurobiol. 47:662–672. 2013. View Article : Google Scholar
13	Sun H, Kosaras B, Klein PM and Jensen FE: Mammalian target of rapamycin complex 1 activation negatively regulates Polo-like kinase 2-mediated homeostatic compensation following neonatal seizures. Proc Natl Acad Sci USA. 110:5199–5204. 2013. View Article : Google Scholar : PubMed/NCBI
14	Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, et al: Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 112:2489–2499. 2008. View Article : Google Scholar : PubMed/NCBI
15	Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K and Miyamoto S: Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res. 6:1356–1364. 2008. View Article : Google Scholar : PubMed/NCBI
16	Park JW, Park ES, Choi EN, Park HY and Jung SC: Altered brain gene expression profiles associated with the pathogenesis of phenylketonuria in a mouse model. Clin Chim Acta. 401:90–99. 2009. View Article : Google Scholar
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
18	Phillips IR and Shephard EA: Cytochrome P450 Protocols. Humana Press; Totowa, NJ: 2006
19	Reinke LA and Moyer MJ: p-Nitrophenol hydroxylation. A microsomal oxidation which is highly inducible by ethanol. Drug Metab Dispos. 13:548–552. 1985.PubMed/NCBI
20	Matsunaga N, Ikeda M, Takiguchi T, Koyanagi S and Ohdo S: The molecular mechanism regulating 24-hour rhythm of CYP2E1 expression in the mouse liver. Hepatology. 48:240–251. 2008. View Article : Google Scholar : PubMed/NCBI
21	Park JW, Lee MH, Choi JO, Park HY and Jung SC: Tissue-specific activation of mitogen-activated protein kinases for expression of transthyretin by phenylalanine and its metabolite, phenylpyruvic acid. Exp Mol Med. 42:105–115. 2010. View Article : Google Scholar :
22	Wong FW, Chan WY and Lee SS: Resistance to carbon tetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol Appl Pharmacol. 153:109–118. 1998. View Article : Google Scholar
23	Kang JS, Wanibuchi H, Morimura K, Wongpoomchai R, Chusiri Y, Gonzalez FJ and Fukushima S: Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity. Toxicol Appl Pharmacol. 228:295–300. 2008. View Article : Google Scholar : PubMed/NCBI
24	Lee SS, Buters JT, Pineau T, Fernandez-Salguero P and Gonzalez FJ: Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem. 271:12063–12067. 1996. View Article : Google Scholar : PubMed/NCBI
25	Patel SJ, Milwid JM, King KR, Bohr S, Iracheta-Vellve A, Li M, Vitalo A, Parekkadan B, Jindal R and Yarmush ML: Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol. 30:179–183. 2012. View Article : Google Scholar : PubMed/NCBI
26	Ueno T and Gonzalez FJ: Transcriptional control of the rat hepatic CYP2E1 gene. Mol Cell Biol. 10:4495–4505. 1990. View Article : Google Scholar : PubMed/NCBI
27	Liu SY and Gonzalez FJ: Role of the liver-enriched transcription factor HNF-1 alpha in expression of the CYP2E1 gene. DNA Cell Biol. 14:285–293. 1995. View Article : Google Scholar : PubMed/NCBI
28	Cheung C, Akiyama TE, Kudo G and Gonzalez FJ: Hepatic expression of cytochrome P450s in hepatocyte nuclear factor 1-alpha (HNF1alpha)-deficient mice. Biochem Pharmacol. 66:2011–2020. 2003. View Article : Google Scholar : PubMed/NCBI
29	Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P, Abbruzzese JL and McConkey DJ: Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res. 65:11510–11519. 2005. View Article : Google Scholar : PubMed/NCBI
30	Armstrong JL, Flockhart R, Veal GJ, Lovat PE and Redfern CP: Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells. J Biol Chem. 285:6091–6100. 2010. View Article : Google Scholar :
31	Hur KY, So JS, Ruda V, Frank-Kamenetsky M, Fitzgerald K, Koteliansky V, Iwawaki T, Glimcher LH and Lee AH: IRE1α activation protects mice against acetaminophen-induced hepatotoxicity. J Exp Med. 209:307–318. 2012. View Article : Google Scholar : PubMed/NCBI
32	Lee AS: The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods. 35:373–381. 2005. View Article : Google Scholar : PubMed/NCBI
33	Oyadomari S and Mori M: Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 11:381–389. 2004. View Article : Google Scholar
34	Basseri S, Lhoták S, Sharma AM and Austin RC: The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response. J Lipid Res. 50:2486–2501. 2009. View Article : Google Scholar : PubMed/NCBI
35	Tong X, Dong S, Yu M, Wang Q and Tao L: Role of heteromeric gap junctions in the cytotoxicity of cisplatin. Toxicology. 310:53–60. 2013. View Article : Google Scholar : PubMed/NCBI
36	Asamoto M, Hokaiwado N, Murasaki T and Shirai T: Connexin 32 dominant-negative mutant transgenic rats are resistant to hepatic damage by chemicals. Hepatology. 40:205–210. 2004. View Article : Google Scholar : PubMed/NCBI
37	Herrmann J, Ciechanover A, Lerman LO and Lerman A: The ubiquitin-proteasome system in cardiovascular diseases - a hypothesis extended. Cardiovasc Res. 61:11–21. 2004. View Article : Google Scholar : PubMed/NCBI
38	Mani A and Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 23:4776–4789. 2005. View Article : Google Scholar : PubMed/NCBI
39	Ciechanover A and Brundin P: The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron. 40:427–446. 2003. View Article : Google Scholar : PubMed/NCBI
40	Goasduff T and Cederbaum AI: NADPH-dependent microsomal electron transfer increases degradation of CYP2E1 by the proteasome complex: role of reactive oxygen species. Arch Biochem Biophys. 370:258–270. 1999. View Article : Google Scholar : PubMed/NCBI
41	Roberts BJ: Evidence of proteasome-mediated cytochrome P-450 degradation. J Biol Chem. 272:9771–9778. 1997.PubMed/NCBI
42	Park HS, Jun Y, Han CR, Woo HJ and Kim YH: Proteasome inhibitor MG132-induced apoptosis via ER stress-mediated apoptotic pathway and its potentiation by protein tyrosine kinase p56lck in human Jurkat T cells. Biochem Pharmacol. 82:1110–1125. 2011. View Article : Google Scholar : PubMed/NCBI
43	Levêque D, Carvalho MC and Maloisel F: Review. Clinical pharmacokinetics of bortezomib. In Vivo. 21:273–278. 2007.PubMed/NCBI
44	Pérez MJ and Cederbaum AI: Proteasome inhibition potentiates CYP2E1-mediated toxicity in HepG2 cells. Hepatology. 37:1395–1404. 2003. View Article : Google Scholar : PubMed/NCBI
45	Fernandes R, Girão H and Pereira P: High glucose down-regulates intercellular communication in retinal endothelial cells by enhancing degradation of connexin 43 by a proteasome-dependent mechanism. J Biol Chem. 279:27219–27224. 2004. View Article : Google Scholar : PubMed/NCBI
46	Minogue PJ, Beyer EC and Berthoud VM: A connexin50 mutant, CX50fs, that causes cataracts is unstable, but is rescued by a proteasomal inhibitor. J Biol Chem. 288:20427–20434. 2013. View Article : Google Scholar : PubMed/NCBI
47	Laing JG, Tadros PN, Westphale EM and Beyer EC: Degradation of connexin43 gap junctions involves both the proteasome and the lysosome. Exp Cell Res. 236:482–492. 1997. View Article : Google Scholar : PubMed/NCBI
48	Huang T, Wan Y, Zhu Y, Fang X, Hiramatsu N, Hayakawa K, Paton AW, Paton JC, Kitamura M and Yao J: Downregulation of gap junction expression and function by endoplasmic reticulum stress. J Cell Biochem. 107:973–983. 2009. View Article : Google Scholar : PubMed/NCBI
49	Larson AM: Acetaminophen hepatotoxicity. Clin Liver Dis. 11:525–548. vi2007. View Article : Google Scholar : PubMed/NCBI
50	Farfel-Becker T, Vitner E, Dekel H, Leshem N, Enquist IB, Karlsson S and Futerman AH: No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum Mol Genet. 18:1482–1488. 2009. View Article : Google Scholar : PubMed/NCBI
51	Hetz C, Lee AH, Gonzalez-Romero D, Thielen P, Castilla J, Soto C and Glimcher LH: Unfolded protein response transcription factor XBP-1 does not influence prion replication or pathogenesis. Proc Natl Acad Sci USA. 105:757–762. 2008. View Article : Google Scholar : PubMed/NCBI